Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $53,373 - $191,449
23,206 Added 71.91%
55,476 $148,000
Q4 2022

Feb 14, 2023

BUY
$6.29 - $11.01 $202,978 - $355,292
32,270 New
32,270 $266,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $62.4M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Atom Investors LP Portfolio

Follow Atom Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Atom Investors LP with notifications on news.